Updates

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.

Dr Jon E. Grant talks about the genetics, neurobiology, and cognitive processes of body-focused repetitive behaviors, which include trichotillomania, skin picking, and other behaviors.

In all, 51.9% of patients entered with or achieved complete disease clearance at least once during the 48-week study.

Can you diagnose this month's dermatology case?